Quick Answer
PROVECTUS BIOPHARMACEUTICALS, INC. reported R&D Expense of $1.90 million for fiscal year 2025.
PROVECTUS BIOPHARMACEUTICALS, INC. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $1.90M | -7.5% |
| 2024 | $2.05M | +17.2% |
| 2023 | $1.75M | -26.8% |
| 2022 | $2.39M | -8.4% |
| 2021 | $2.61M | -7.3% |
| 2020 | $2.81M | -29.7% |
| 2019 | $4.00M | -15.7% |
| 2018 | $4.75M | -42.1% |
| 2017 | $8.20M | -0.1% |
| 2016 | $8.21M | -27.8% |
| 2015 | $11.38M | +95.9% |
| 2014 | $5.81M | +61.6% |
| 2013 | $3.60M | -28.2% |
| 2012 | $5.01M | -43.2% |
| 2011 | $8.81M | +4.6% |
| 2010 | $8.42M | +71.5% |
| 2009 | $4.91M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $345.9K | -16.5% | -60.1% |
| June 30, 2025 | $867.3K | +83.4% | +123.1% |
| March 31, 2025 | $388.8K | -30.0% | -6.1% |
| September 30, 2024 | $414.0K | +18.0% | -12.5% |
| June 30, 2024 | $472.9K | +8.9% | -14.9% |
| March 31, 2024 | $555.5K | +1.3% | +58.4% |
| September 30, 2023 | $350.8K | -39.6% | -19.2% |
| June 30, 2023 | $434.2K | -46.8% | -20.8% |
- PROVECTUS BIOPHARMACEUTICALS, INC. showed a decrease of -7.5% in R&D Expense compared to the prior fiscal year.
- Over the 2009–2025 period, PROVECTUS BIOPHARMACEUTICALS, INC.’s r&d expense has declined by 61.4% (from $4.91 million to $1.90 million).
- The most recent figure is from PROVECTUS BIOPHARMACEUTICALS, INC.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: